The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children
Open accessAbstract
BACKGROUND: The candidate malaria vaccine RTS,S/AS01 is being evaluated in order to inform a decision regarding its inclusion in routine vaccination schedules. METHODS: We conducted 7 years of follow-up in children who had been randomly assigned, at 5 to 17 months of age, to receive three doses of either the RTS,S/AS01 vaccine or a rabies (control) vaccine. The end point was clinical malaria (temperature of ≥37.5°C and infection with Plasmodium falciparum of >2500 parasites per cubic millimeter). In an analysis that was not prespecified, the malaria exposure of each child was estimated with the use of information on the prevalence of malaria among residents within a 1-km radius of the child's home. Vaccine efficacy was defined as 1 minus the hazard ratio or the incidence-rate ratio, multiplied by 100, in the RTS,S/AS01 group versus the control group. RESULTS: Over 7 years of follow-up, we identified 1002 episodes of clinical malaria among 223 children randomly assigned to the RTS,S/AS01 group and 992 episodes among 224 children randomly assigned to the control group. The vaccine efficacy, as assessed by negative binomial regression, was 4.4% (95% confidence interval [CI], -17.0 to 21.9; P=0.66) in the intention-to-treat analysis and 7.0% (95% CI, -14.5 to 24.6; P=0.52) in the per-protocol analysis. Vaccine efficacy waned over time (P=0.006 for the interaction between vaccination and time), including negative efficacy during the fifth year among children with higher-than-average exposure to malaria parasites (intention-to-treat analysis: -43.5%; 95% CI, -100.3 to -2.8 [P=0.03]; per-protocol analysis: -56.8%; 95% CI, -118.7 to -12.3 [P=0.008]). CONCLUSIONS: A three-dose vaccination with RTS,S/AS01 was initially protective against clinical malaria, but this result was offset by rebound in later years in areas with higher-than-average exposure to malaria parasites. (Funded by the PATH Malaria Vaccine Initiative and others; ClinicalTrials.gov number, NCT00872963.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
The RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Self-citationMenendez, C., Kahigwa, E., Hirt, R., Vounatsou, P., Aponte, J. J., Font, F., Acosta, C. J., Schellenberg, D. M., Galindo, C. M., Kimario, J., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04229-3 · Cited by 353
Akl, E. A., Briel, M., You, J. J., Sun, X., Johnston, B. C., Busse, J. W., Mulla, S., Lamontagne, F., Bassler, D., Vera, C., et al. (2012) · BMJ · doi:10.1136/bmj.e2809 · Cited by 350
Trape, J.-F., Tall, A., Diagne, N., Ndiath, O., Ly, A. B., Faye, J., Dieye-Ba, F., Roucher, C., Bouganali, C., Badiane, A., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70194-3 · Cited by 328
Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Awuondo, K. O., Leach, A., Lievens, M., Leboulleux, D., Njuguna, P., Peshu, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207564 · Cited by 270
Self-citationNoor, A. M., Kinyoki, D. K., Mundia, C. W., Kabaria, C. W., Mutua, J. W., Alegana, V. A., Fall, I. S., & Snow, R. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62566-0 · Cited by 263
Bejon, P., Williams, T. N., Nyundo, C., Hay, S. I., Benz, D., Gething, P. W., Otiende, M., Peshu, J., Bashraheil, M. M., Greenhouse, B., et al. (2014) · eLife · doi:10.7554/elife.02130 · Cited by 127
Self-citationBejon, P., Cook, J. A., Bergmann‐Leitner, E. S., Olotu, A., Lusingu, J., Mwacharo, J. K., Vekemans, J., Njuguna, P., Leach, A. J., Lievens, M., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir222 · Cited by 72
Self-citationOdhiambo, F., Hamel, M. J., Williamson, J. M., Lindblade, K. A., ter Kuile, F. O., Peterson, E., Otieno, P., Kariuki, S., VULULE, J. M., Slutsker, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010016 · Cited by 43
Senn, N., Rarau, P., Stanisic, D. I., Robinson, L. J., Barnadas, C., Manong, D., Salib, M., Iga, J., Tarongka, N., Ley, S. D., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001195 · Cited by 43
Estimating Individual Exposure to Malaria Using Local Prevalence of Malaria Infection in the Field
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G. M., Ogada, E. A., DRAKELEY, C. J., Marsh, K., & Bejon, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032929 · Cited by 42
Self-citationCampo, J. J., Aponte, J. J., Skinner, J., Nakajima, R., Molina, D. M., Liang, L., Sacarlal, J., Alonso, P. L., Crompton, P. D., Felgner, P. L., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044677 · Cited by 40
Oyediran, A. B., Topley, E., Osunkoya, B. O., et al. (1993) · PubMed · Cited by 9
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
RTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
Datoo, M. S., Natama, M. H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00943-0 · Cited by 452
Metadata
- Authors
- Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D. C., Njuguna, P., Marsh, K., & Bejon, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-30
- Volume
- 374
- Issue
- 26
- Pages
- 2519-2529
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2472994826
- Cited by
- 421
- References
- 16
- FWCI
- 44.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.